GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aldeyra Therapeutics Inc (FRA:137) » Definitions » Price-to-Funds-From-Operations

Aldeyra Therapeutics (FRA:137) Price-to-Funds-From-Operations : (As of Dec. 14, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aldeyra Therapeutics Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Aldeyra Therapeutics Business Description

Traded in Other Exchanges
Address
131 Hartwell Avenue, Suite 320, Lexington, MA, USA, 02421
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.